Using NSCLC patient specimens and xenograft models, we have previously identified an association of EGFR:GRB2 complexes and response to EGFR inhibition [76] and more recently identified a correlation between MET:GRB2 complexes and response to MET kinase inhibitors [77]. This evidence concerns the gene MET and non-small cell lung carcinoma.